Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoff Hall

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic VirusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Seminars in Pediatric Neurology|May 18, 2011
The NeuroDevNet Autism Spectrum Disorders Demonstration ProjectLonnie Zwaigenbaum, Stephen Scherer, Peter Szatmari, et al.
British Journal of Cancer|May 27, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerYvette Drew, Jonathan Ledermann, Geoff Hall, et al.
British Journal of Cancer|March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerYvette Drew, Jonathan Ledermann, Geoff Hall, et al.
BMJ Open|April 2, 2022
Development and validation of multivariable machine learning algorithms to predict risk of cancer in symptomatic patients referred urgently from primary care: a diagnostic accuracy studyRichard Savage, Mike Messenger, Richard D Neal, et al.
Journal of Cancer Survivorship : Research and Practice|December 3, 2024
Quality of life, healthcare usage and finances of UK cancer survivors five years post-diagnosis: a matched controlled studyLorraine Warrington, Kate Absolom, Paul Baxter, et al.
Frontiers in Public Health|December 20, 2016
The Problem with Big Data: Operating on Smaller Datasets to Bridge the Implementation GapRichard P Mann, Faisal Mushtaq, Alan D White, et al.
Gynecologic Oncology|April 8, 2023
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trialSandro Pignata, Amit Oza, Geoff Hall, et al.
British Journal of Cancer|March 18, 2025
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation statusSandro Pignata, Amit Oza, Geoff Hall, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic VirusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Seminars in Pediatric Neurology|May 18, 2011
The NeuroDevNet Autism Spectrum Disorders Demonstration ProjectLonnie Zwaigenbaum, Stephen Scherer, Peter Szatmari, et al.
British Journal of Cancer|May 27, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerYvette Drew, Jonathan Ledermann, Geoff Hall, et al.
British Journal of Cancer|March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerYvette Drew, Jonathan Ledermann, Geoff Hall, et al.
BMJ Open|April 2, 2022
Development and validation of multivariable machine learning algorithms to predict risk of cancer in symptomatic patients referred urgently from primary care: a diagnostic accuracy studyRichard Savage, Mike Messenger, Richard D Neal, et al.
Journal of Cancer Survivorship : Research and Practice|December 3, 2024
Quality of life, healthcare usage and finances of UK cancer survivors five years post-diagnosis: a matched controlled studyLorraine Warrington, Kate Absolom, Paul Baxter, et al.
Frontiers in Public Health|December 20, 2016
The Problem with Big Data: Operating on Smaller Datasets to Bridge the Implementation GapRichard P Mann, Faisal Mushtaq, Alan D White, et al.
Gynecologic Oncology|April 8, 2023
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trialSandro Pignata, Amit Oza, Geoff Hall, et al.
British Journal of Cancer|March 18, 2025
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation statusSandro Pignata, Amit Oza, Geoff Hall, et al.
Pageof 5